Insights

Strategic Focus Targeting medically supervised settings with specialized therapies, Talphera presents opportunities to engage hospital systems, critical care units, and outpatient infusion centers where anticoagulant and device-related therapies are needed.

Breakthrough Recognition Niyad’s Breakthrough Device Designation and IDE study status signal a potential for early-adopter partnerships with hospitals and procurement teams seeking innovative anticoagulation solutions for extracorporeal circuits.

Financing Momentum Recent private funding and prior capital commitments indicate growing investor confidence and near-term visibility for clinical milestones, enabling co-development discussions, milestone-based pilots, and potential funding alliances.

Strategic Partnerships In-licensed pre-filled syringes from Aguettant (Fedsyra and PFS-02) create cross-sell and bundle opportunities within pharmaceutical distributors and centralized purchasing programs serving critical care, anesthesia, and emergency settings.

Market Readiness Participation in major critical care nephrology conferences and ongoing IDE work suggest a window for key opinion leader engagement, case studies, and early-adopter clinical collaborations to accelerate adoption.

Similar companies to Talphera, Inc.

Talphera, Inc. Tech Stack

Talphera, Inc. uses 8 technology products and services including Matomo, WordPress, CookieYes, and more. Explore Talphera, Inc.'s tech stack below.

Media & News

Talphera, Inc.'s Email Address Formats

Talphera, Inc. uses at least 2 email formats:
Talphera, Inc. Email FormatsExamplePercentage
FLast@acelrx.comJDoe@acelrx.com
91%
Last@acelrx.comDoe@acelrx.com
9%

Frequently Asked Questions

What is Talphera, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Talphera, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Talphera, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Talphera, Inc. is a publicly traded company; the company's stock symbol is TLPH.

What is Talphera, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Talphera, Inc.'s official website is talphera.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Talphera, Inc. generate?

Minus sign iconPlus sign icon
As of August 2026, Talphera, Inc.'s annual revenue is estimated to be <$1M.

What is Talphera, Inc.'s NAICS code?

Minus sign iconPlus sign icon
Talphera, Inc.'s NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Talphera, Inc. have currently?

Minus sign iconPlus sign icon
As of August 2026, Talphera, Inc. has approximately 39 employees across 2 continents, including North America and Asia. Key team members include Cfo: R. A., Director And Chief Executive Officer: V. A. and Associate Director Pharmaceutical Engineering: J. A. Explore Talphera, Inc.'s employee directory with LeadIQ.

What industry does Talphera, Inc. belong to?

Minus sign iconPlus sign icon
Talphera, Inc. operates in the Pharmaceutical Manufacturing industry.

What technology does Talphera, Inc. use?

Minus sign iconPlus sign icon
Talphera, Inc.'s tech stack includes Matomo, WordPress, CookieYes, Mimecast, JSON-LD, KnowBe4, X-XSS-Protection and Astra.

What is Talphera, Inc.'s email format?

Minus sign iconPlus sign icon
Talphera, Inc.'s email format typically follows the pattern of FLast@acelrx.com. Find more Talphera, Inc. email formats with LeadIQ.

How much funding has Talphera, Inc. raised to date?

Minus sign iconPlus sign icon
As of August 2026, Talphera, Inc. has raised $213M in funding. The last funding round occurred on Sep 08, 2025 for $17M.

When was Talphera, Inc. founded?

Minus sign iconPlus sign icon
Talphera, Inc. was founded in 2005.
Talphera, Inc. logo

Talphera, Inc.

Pharmaceutical ManufacturingCalifornia, United States11-50 Employees

Talphera, Inc., based in San Mateo, California, is a specialty pharmaceutical company focused on developing and commercializing therapies for use in medically supervised settings. Its lead product candidate, Niyad, is a lyophilized formulation of nafamostat evaluated under an investigational device exemption as an anticoagulant for the extracorporeal circuit, and it has received Breakthrough Device Designation from the FDA. The company has also in-licensed two pre-filled syringes from Aguettant for ephedrine and phenylephrine delivery, namely Fedsyra and PFS-02.

Talphera targets healthcare providers and facilities that perform extracorporeal therapies and require specialized anticoagulation and vasopressor delivery options. A recent development includes Talphera announcing the acceptance of two abstracts for presentation at the 31st Annual International Conference on Advances in Critical Care Nephrology: AKI & CRRT 2026.

Section iconCompany Overview

Phone number
Stock Symbol
TLPH
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2005
Employees
11-50

Section iconFunding & Financials

  • $213M

    Talphera, Inc. has raised a total of $213M of funding over 14 rounds. Their latest funding round was raised on Sep 08, 2025 in the amount of $17M as a Post IPO Equity.

  • <$1M

    Talphera, Inc.'s revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.